CD 2027

Galderma R&D · Phase 2 active Small molecule

At a glance

Generic name	CD 2027
Also known as	Calcitriol
Sponsor	Galderma R&D
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis (PHASE2)
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CD 2027 CI brief — competitive landscape report
CD 2027 updates RSS · CI watch RSS
Galderma R&D portfolio CI